Comment: HPV-targeted adoptive T cell therapy may provide a new strategy for advanced cervical cancer

ASCO 2014 roundup

Lower-dose radiation safe for certain lower-risk, HPV-positive head and neck cancers

Blinatumomab shown to be beneficial in relapsed/refractory B-precursor acute lymphoblastic leukaemia

Phase III SELECT trial shows lenvatinib to be effective in resistant thyroid cancer

Adding lapatinib to adjuvant trastuzumab does not improve outcomes in early- stage HER2-positive breast cancer

Adding lapatinib to adjuvant trastuzumab does not improve outcomes in early-stage HER2-positive breast cancer

Adjuvant exemestane more effective than tamoxifen when combined with ovarian function suppression in young women with hormone-sensitive, early-stage breast cancer

Targeted drug combo, cediranib plus olaparib, significantly increases progression-free survival in recurrent ovarian cancer

Lenvatinib yields high response rates and delays progression in radioiodine-resistant, advanced differentiated thyroid cancer

Second-line treatment with ramucirumab plus docetaxel extends survival in advanced NSCLC

Cancer evasion of the immune system: the fundamentals